AbbVie Stock Price, News & Analysis (NYSE:ABBV)

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABBV shares.
View ABBV analyst ratings or view top-rated stocks.

16 brokerages have issued 1-year price targets for AbbVie's shares. Their ABBV share price targets range from $150.00 to $196.00. On average, they expect the company's stock price to reach $167.94 in the next twelve months. This suggests a possible upside of 16.5% from the stock's current price.
View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts.

AbbVie's stock was trading at $161.61 at the beginning of 2023. Since then, ABBV shares have decreased by 10.8% and is now trading at $144.14.
View the best growth stocks for 2023 here.

AbbVie saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 11,150,000 shares, a decrease of 15.7% from the October 31st total of 13,230,000 shares. Based on an average daily trading volume, of 4,700,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 0.6% of the shares of the stock are sold short.
View AbbVie's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our ABBV earnings forecast.

AbbVie Inc. (NYSE:ABBV) released its earnings results on Friday, October, 27th. The company reported $2.95 earnings per share for the quarter, beating the consensus estimate of $2.86 by $0.09. The firm earned $13.93 billion during the quarter, compared to the consensus estimate of $13.72 billion. AbbVie had a trailing twelve-month return on equity of 152.70% and a net margin of 11.81%. AbbVie's quarterly revenue was down 6.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.66 EPS.
Read the conference call transcript.

AbbVie declared a quarterly dividend on Friday, October 27th. Shareholders of record on Tuesday, January 16th will be paid a dividend of $1.55 per share on Thursday, February 15th. This represents a $6.20 annualized dividend and a dividend yield of 4.30%. The ex-dividend date of this dividend is Friday, January 12th. This is a positive change from the stock's previous quarterly dividend of $1.48.
Read our dividend analysis for ABBV.

AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 4.13%. ABBV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 162.19%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 53.05% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

ETFs with the largest weight of AbbVie (NYSE:ABBV) stock in their portfolio include First Trust Morningstar Dividend Leaders Index (FDL), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Horizon Kinetics Medical ETF (MEDX), iShares Core High Dividend ETF (HDV), Invesco Pharmaceuticals ETF (PJP), Simplify Health Care ETF (PINK), Health Care Select Sector SPDR Fund (XLV) and VanEck Pharmaceutical ETF (PPH).

AbbVie updated its FY24 earnings guidance on Friday, October, 27th. The company provided earnings per share (EPS) guidance of $10.70-11.00 for the period, compared to the consensus EPS estimate of $11.11.

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Rogers Communications (RCI) and Open Text (OTEX).

AbbVie's stock is owned by many different retail and institutional investors. Top institutional investors include Morgan Stanley (1.82%), Charles Schwab Investment Management Inc. (1.29%), Northern Trust Corp (1.24%), Bank of New York Mellon Corp (1.15%), Ameriprise Financial Inc. (0.80%) and Legal & General Group Plc (0.69%). Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents and Timothy J Richmond.
View institutional ownership trends.

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.